Mycophenolate use in dermatology: a clinical audit.
作者： Jane Li , Alvin H Chong , Jack Green , Robert Kelly , Christopher Baker
DOI: 10.1111/AJD.12042
关键词:
摘要: Mycophenolate use in dermatology is growing due to its reputation as a steroid-sparing agent with favourable side-effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted retrospective clinical audit 33 patients who had received at our institution between April 2010 January 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent showed some benefit from treatment, 12 failing respond. Side-effects were experienced 45 patients, two whom serious side-effects. Female sex appears be risk factor adverse effects. conclude that although promising across variety conditions, further randomised controlled trials required.
sci-hub.se 参考文章(44)
Matthias Behrend, Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Safety. ,vol. 24, pp. 645- 663 ,(2001) , 10.2165/00002018-200124090-00002
R. Robson, J.M. Cecka, G. Opelz, M. Budde, S. Sacks, Prospective Registry-Based Observational Cohort Study of the Long-Term Risk of Malignancies in Renal Transplant Patients Treated with Mycophenolate Mofetil American Journal of Transplantation. ,vol. 5, pp. 2954- 2960 ,(2005) , 10.1111/J.1600-6143.2005.01125.X
M Akhyani, C Chams-Davatchi, MR Hemami, S Fateh, Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. Journal of The European Academy of Dermatology and Venereology. ,vol. 24, pp. 1447- 1451 ,(2010) , 10.1111/J.1468-3083.2010.03667.X
Stefan Beissert, Thomas Werfel, Uta Frieling, Markus Böhm, Michael Sticherling, Rudolf Stadler, Detlef Zillikens, Berthold Rzany, Nicolas Hunzelmann, Michael Meurer, Harald Gollnick, Thomas Ruzicka, Hans Pillekamp, Volker Junghans, Gisela Bonsmann, Thomas A. Luger, A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus Archives of Dermatology. ,vol. 142, pp. 1447- 1454 ,(2006) , 10.1001/ARCHDERM.143.12.1536
D.J. Kouba, D. Mimouni, A. Rencic, H.C. Nousari, Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. British Journal of Dermatology. ,vol. 148, pp. 147- 148 ,(2003) , 10.1046/J.1365-2133.2003.05042.X
William S. Lynch, Mycophenolic Acid for Psoriasis Archives of Dermatology. ,vol. 113, pp. 1203- 1208 ,(1977) , 10.1001/ARCHDERM.1977.01640090051004
Christina Rogalski, Michael Sticherling, Panarteritis cutanea benigna--an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. International Journal of Dermatology. ,vol. 46, pp. 817- 821 ,(2007) , 10.1111/J.1365-4632.2007.02975.X
Stephan T. Stern, Melanie N. Tallman, Kristini K. Miles, Joseph K. Ritter, Robert E. Dupuis, Philip C. Smith, Gender-related differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats. Drug Metabolism and Disposition. ,vol. 35, pp. 449- 454 ,(2007) , 10.1124/DMD.106.012013
N Basara, M.G Kiehl, W Blau, E Römer, M Bischoff, B Schmetzer, D Kirsten, S Günzelmann, A.A Fauser, Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. International Conference on New Trends in Clinical and Experimental Immunosuppression. ,vol. 33, pp. 2121- 2123 ,(2001) , 10.1016/S0041-1345(01)01968-6
Richard N. Herrier, Advances in the treatment of moderate-to-severe plaque psoriasis American Journal of Health-system Pharmacy. ,vol. 68, pp. 795- 806 ,(2011) , 10.2146/AJHP100227